Cardio Diagnostics Holdings (Nasdaq: CDIO) has announced partnerships with seven new provider organizations across multiple U.S. regions to expand the reach of its AI-driven cardiovascular tests, Epi+Gen CHD™ and PrecisionCHD™. The new partners include specialized practices in Michigan, Illinois, Texas, Florida, California, and Connecticut, representing various medical specialties including concierge medicine, primary care, and precision medicine.
These partnerships aim to leverage Cardio Diagnostics’ advanced genetic and epigenetic testing technology to provide actionable insights into coronary heart disease and heart attack risk, enabling personalized treatment plans. The company’s solutions combine epigenetics, genetics, and AI to offer deeper insights into heart disease risk, status, and underlying drivers.
Cardio Diagnostics Holdings (Nasdaq: CDIO) ha annunciato partnership con sette nuove organizzazioni fornitrici in diverse regioni degli Stati Uniti per ampliare la portata dei suoi test cardiovascolari guidati dall’IA, Epi+Gen CHD™ e PrecisionCHD™. I nuovi partner includono studi specializzati in Michigan, Illinois, Texas, Florida, California e Connecticut, rappresentando diverse specialità mediche tra cui medicina concierge, assistenza primaria e medicina di precisione.
Queste partnership mirano a sfruttare la tecnologia avanzata di test genetici ed epigenetici di Cardio Diagnostics per fornire approfondimenti utili sulla malattia coronarica e il rischio di infarto, consentendo piani di trattamento personalizzati. Le soluzioni dell’azienda combinano epigenetica, genetica e IA per offrire approfondimenti più approfonditi sul rischio di malattie cardiache, sullo stato e sui fattori sottostanti.
Cardio Diagnostics Holdings (Nasdaq: CDIO) ha anunciado asociaciones con siete nuevas organizaciones proveedoras en varias regiones de EE. UU. para ampliar el alcance de sus pruebas cardiovasculares impulsadas por IA, Epi+Gen CHD™ y PrecisionCHD™. Los nuevos socios incluyen prácticas especializadas en Michigan, Illinois, Texas, Florida, California y Connecticut, que representan diversas especialidades médicas, incluido el conocimiento de medicina concierge, atención primaria y medicina de precisión.
Estas asociaciones tienen como objetivo aprovechar la avanzada tecnología de pruebas genéticas y epigenéticas de Cardio Diagnostics para proporcionar información procesable sobre la enfermedad coronaria y el riesgo de infarto, permitiendo planes de tratamiento personalizados. Las soluciones de la compañía combinan epigenética, genética e IA para ofrecer conocimientos más profundos sobre el riesgo de enfermedades cardíacas, su estado y los factores subyacentes.
카디오 진단 홀딩스 (Nasdaq: CDIO)는 미국의 여러 지역에 있는 7개의 새로운 제공 기관과 파트너십을 발표하여 AI 기반 심혈관 테스트인 Epi+Gen CHD™ 및 PrecisionCHD™의 범위를 확장했습니다. 새로운 파트너에는 미시간, 일리노이, 텍사스, 플로리다, 캘리포니아 및 코네티컷의 전문 진료가 포함되어 있으며, 컨시어지 의학, 일차 진료 및 정밀 의학 등 다양한 의료 전문 분야를 대표합니다.
이러한 파트너십은 카디오 진단의 고급 유전자 및 후천적 유전자 검사 기술을 활용하여 관상 동맥 질환 및 심장 마비 위험에 대한 실행 가능한 통찰력을 제공하고 개인 맞춤형 치료 계획을 가능하게 하는 것을 목표로 하고 있습니다. 회사의 솔루션은 후천 유전학, 유전학 및 AI를 결합하여 심장 질환의 위험, 상태 및 근본 원인에 대한 더 깊은 통찰력을 제공합니다.
Cardio Diagnostics Holdings (Nasdaq: CDIO) a annoncé des partenariats avec sept nouvelles organisations fournissant des services dans plusieurs régions des États-Unis pour élargir la portée de ses tests cardiovasculaires pilotés par l’IA, Epi+Gen CHD™ et PrecisionCHD™. Les nouveaux partenaires comprennent des cabinets spécialisés dans le Michigan, l’Illinois, le Texas, la Floride, la Californie et le Connecticut, représentant diverses spécialités médicales, y compris la médecine concierge, les soins primaires et la médecine de précision.
Ces partenariats visent à tirer parti de la technologie avancée de tests génétiques et épigénétiques de Cardio Diagnostics pour fournir des informations exploitables sur la maladie coronarienne et le risque de crise cardiaque, permettant ainsi des plans de traitement personnalisés. Les solutions de l’entreprise combinent épigénétique, génétique et IA pour offrir des informations plus approfondies sur le risque de maladies cardiaques, leur état et les facteurs sous-jacents.
Cardio Diagnostics Holdings (Nasdaq: CDIO) hat Partnerschaften mit sieben neuen Anbieterorganisationen in mehreren Regionen der USA angekündigt, um die Reichweite seiner KI-gesteuerten kardiovaskulären Tests, Epi+Gen CHD™ und PrecisionCHD™, zu erweitern. Zu den neuen Partnern gehören spezialisierte Praxen in Michigan, Illinois, Texas, Florida, Kalifornien und Connecticut, die verschiedene medizinische Spezialitäten vertreten, darunter Concierge-Medizin, Primärversorgung und präzisionsmedizinische Ansätze.
Diese Partnerschaften zielen darauf ab, die fortschrittliche genetische und epigenetische Testtechnologie von Cardio Diagnostics zu nutzen, um umsetzbare Einblicke in koronare Herzkrankheit und das Risiko eines Herzinfarkts zu bieten und personalisierte Behandlungspläne zu ermöglichen. Die Lösungen des Unternehmens kombinieren Epigenetik, Genetik und KI, um tiefere Einblicke in das Risiko von Herzkrankheiten, deren Status und zugrunde liegende Faktoren zu bieten.
Positive
- Expansion of market presence through seven new provider partnerships across multiple U.S. regions
- Diversification of service adoption across various medical specialties and practice types
- Strategic positioning in the growing precision cardiovascular medicine market
Insights
The strategic partnership expansion with seven diverse healthcare providers represents a significant commercial milestone for Cardio Diagnostics. The new partnerships span multiple regions and specialties, including concierge practices, primary care and precision medicine clinics, demonstrating broad market acceptance of their Epi+Gen CHD™ and PrecisionCHD™ tests.
The integration of these tests into various practice types – from functional medicine to longevity clinics – validates their versatility and clinical utility. Particularly noteworthy is the adoption by providers focused on preventive care and personalized medicine, suggesting strong product-market fit in the growing precision medicine sector.
The geographical diversification across the Midwest, South, West and Northeast regions establishes a foundation for scalable growth. Each new provider organization represents a potential recurring revenue stream, as cardiovascular testing is often ongoing for at-risk patients. The partnership with practices emphasizing prevention and early detection aligns perfectly with the current healthcare shift toward preventive medicine and value-based care models.
From a market perspective, these partnerships could accelerate adoption rates through peer validation and clinical evidence generation. The diverse provider base will likely generate valuable real-world data, potentially strengthening the company’s competitive position and supporting future reimbursement discussions with payers.
The strategic significance of these partnerships extends beyond mere geographic expansion. By targeting providers who emphasize preventive care, longevity and precision medicine, Cardio Diagnostics is positioning its tests within high-value clinical workflows where advanced diagnostics command premium pricing.
The business model implications are substantial. These partnerships can create multiple revenue streams through:
- Direct test revenue from patient care
- Potential data monetization opportunities
- Clinical validation strengthening future payer negotiations
The focus on concierge practices and precision medicine clinics is particularly strategic, as these providers typically serve patients willing to pay out-of-pocket for advanced diagnostics. This could accelerate revenue generation while the company builds its case for broader insurance coverage.
The diversity of practice types also provides natural hedge against reimbursement risks, as the company isn’t overly dependent on any single healthcare delivery model. The emphasis on preventive care aligns with emerging value-based care models, potentially positioning Cardio Diagnostics to benefit from future healthcare payment reforms.
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced that the Company has partnered with seven new provider organizations. This expansion highlights the growing adoption of the Company’s cutting-edge blood tests, Epi+Gen CHD™ and PrecisionCHD™, designed to transform the prevention, detection, and management of coronary heart disease.
The new provider organizations span various regions and medical specialties including:
Midwest
-
A forward-thinking concierge practice in
Michigan , whose providers emphasize wellness and preventive health. Its services include weight management, hormone replacement therapy, hair loss treatment among many other personalized treatment plans using the latest medical technologies. -
A practice located in
Illinois , offering a variety of primary care services including routine laboratory testing, vaccinations, and diabetes management, with a unique patient-centered approach to treating hypertension, COPD, and other chronic diseases. -
A practice in
Illinois with a focus on preventive care, diagnosis and treatment of chronic conditions and disease through the lens of longevity. Its providers take a science-based approach to helping their patients stay healthy for longer.
South
-
A practice in
Texas , that employs concierge-level of care personalized for the patient and offers a holistic medicine approach. This practice emphasizes prevention, reduction of hospital admissions and high levels of patient satisfaction, which align closely with Cardio Diagnostic’s approach to risk identification and early detection. -
A practice in
Florida that emphasizes a functional medicine approach to whole-body healing, understanding the root cause of imbalance rather than merely managing symptoms. Its providers are health experts and coaches that help patients manage chronic conditions including inflammation, hypertension, GI issues, and hormonal imbalances.
West
-
A Precision Medicine practice in
California , that incorporates individual variability in genes, environment and lifestyle when considering the appropriate care plan for a patient. Cardio Diagnostics’ epigenetics tests are a perfect complement to the practice that emphasizes both the prevention and precision management of chronic diseases such as heart disease and diabetes.
Northeast
-
A practice in
Connecticut led by a leading longevity provider in the areas of internal medicine, sports medicine and concierge medicine, that is a pioneer in the field of applied clinical genomics.
By integrating Epi+Gen CHD™ and PrecisionCHD™ into their practices, providers can leverage the Company’s advanced genetic and epigenetic testing technology to obtain actionable insights into coronary heart disease, heart attack risk and help guide personalized treatment plans for their patients. Ultimately, these solutions can help address the rising prevalence of cardiovascular disease across various patient demographics.
The addition of these new provider partners underscores the growing adoption of Cardio Diagnostics’ solutions across a wide variety of clinical settings. As providers nationwide continue to recognize the value of Precision Cardiovascular Medicine, the Company’s innovative tests are becoming essential tools in managing heart health more effectively.
“We continue to make meaningful strides in our mission to enable providers with actionable clinical intelligence that goes beyond proxy biomarkers such as cholesterol,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “By equipping practices with our Epi+Gen CHD™ and PrecisionCHD™ tests, we’re enhancing patient care, driving better outcomes, and making Precision Cardiovascular Medicine more accessible.”
Cardio Diagnostics’ solutions uniquely combine epigenetics, genetics and AI to provide deep insights into heart disease risk, status and their drivers. With coronary heart disease remaining the leading cause of death globally, these tools are crucial for both early detection and ongoing management.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.CDIO.AI.
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2023 and Form 10-Q for the period ended in September 30, 2024, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com:
Investors:
Investor Relations
855-226-9991
[email protected]
Media & Public Relations:
Public Relations
855-226-9991
[email protected]
Source: Cardio Diagnostics
FAQ
What new partnerships did Cardio Diagnostics (CDIO) announce in 2024?
Cardio Diagnostics announced partnerships with seven new provider organizations across various U.S. regions, including practices in Michigan, Illinois, Texas, Florida, California, and Connecticut.
What tests are being offered through CDIO’s new provider partnerships?
The partnerships will offer Cardio Diagnostics’ Epi+Gen CHD™ and PrecisionCHD™ tests, which combine epigenetics, genetics, and AI for cardiovascular disease assessment.
How will CDIO’s new partnerships impact patient care?
The partnerships will enable providers to obtain actionable insights into coronary heart disease and heart attack risk, helping guide personalized treatment plans and improve patient care outcomes.
What regions are covered by CDIO’s new provider partnerships?
The new provider partnerships cover multiple U.S. regions including the Midwest (Michigan, Illinois), South (Texas, Florida), West (California), and Northeast (Connecticut).
link